Loading patent…
AssigneesThe Hong Kong Polytechnic University, Wayne State University, Moffitt Cancer Center
InventorsTak-Hang Chan, Wai-Har Lam, Larry Chow, Qing Dou, Deborah Kuhn, Aslamuzzaman Kazi
Estimating the term…
(−)-EGCG, the most abundant catechin, was found to be chemopreventive and anticancer agent. However, (−)-EGCG has at least one limitation: it gives poor bioavailability. This invention provides compounds of generally formula 10, wherein R1 is selected from the group of —H and C1 to C6 acyl group; R2, R3, and R4 are each independently selected from the group of —H, —OH, and C1 to C6 acyloxyl group; and at least one of R2, R3, or R4 is —H. The derivatives of (−)-EGCG that is at least as potent as (−)-EGCG. The carboxylate protected forms of (−)-EGCG and its derivatives are found to be more stable than the unprotected forms, which can be used as proteasome inhibitors to reduce tumor cell growth.
A compound for inhibiting proteasome having the formula:
4-5. (canceled)
8-9. (canceled)
A method of reducing tumor cell growth comprising the step of administering an effective amount of a compound having the formula:
(canceled)
A compound for inhibiting proteasome having the formula:
A compound for inhibiting proteasome having one of the following formulae 10A or 10B:
Dependencies are inferred from the claim text.